2018
Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience
Sawas A, Kuruvilla J, Lue J, Deng C, Amengual J, Montanari F, Savage K, Elgedawe H, Villa D, Crump M, Connors J, O'Connor O. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood 2018, 132: 2907. DOI: 10.1182/blood-2018-99-117251.Peer-Reviewed Original ResearchAutologous stem cell transplantProgression-free survivalRefractory Hodgkin lymphomaComplete response rateDose limiting toxicitiesHigh-dose chemotherapyOverall response rateHodgkin's lymphomaBrentuximab vedotinOverall survivalDay 1Partial responseMedian numberDose levelsPrior autologous stem cell transplantResponse rateAutologous stem cell transplantationSeattle GeneticsPhase II dosePhysician's choice chemotherapyPrior radiation therapyPrior systemic therapyLong-term respondersSubset of patientsEvidence of relapse
2008
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals Of Oncology 2008, 19: 1331-1335. PMID: 18344536, DOI: 10.1093/annonc/mdn044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, CD34Antineoplastic Combined Chemotherapy ProtocolsBleomycinBone Marrow PurgingCombined Modality TherapyCyclophosphamideCytarabineDisease ProgressionDisease-Free SurvivalDoxorubicinDrug Administration ScheduleEtoposideFemaleFollow-Up StudiesGenes, bcl-2Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansImmunologic FactorsImmunosuppressive AgentsKaplan-Meier EstimateLymphoma, FollicularMaleMiddle AgedMultivariate AnalysisPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionRituximabTime FactorsTransplantation, AutologousTreatment OutcomeVincristineConceptsProgression-free survivalRefractory follicular lymphomaHigh-dose therapyFollicular lymphomaFive-year progression-free survivalPeripheral blood stem cell mobilizationBlood stem cell mobilizationEnd pointHigh-dose AraC.Persistent clinical remissionPrimary end pointSecondary end pointsStem cell harvestStem cell mobilizationBcl-2 rearrangementClinical remissionComplete remissionMolecular remissionPartial responseComplete responseClinical outcomesCell mobilizationMedian numberImmunochemotherapyPatients
2004
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma
Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplantation 2004, 34: 175-179. PMID: 15170171, DOI: 10.1038/sj.bmt.1704551.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsB-LymphocytesBone Marrow PurgingCytarabineFemaleHematopoietic Stem Cell MobilizationHumansImmunophenotypingLymphoma, FollicularLymphoma, Mantle-CellMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRituximabSalvage TherapyTransplantation, AutologousConceptsB-cell depletionHD cytarabineB cellsCell lymphomaPeripheral blood stem cell mobilizationBlood stem cell mobilizationRefractory mantle cell lymphomaHigh-dose AraCRefractory follicular lymphomaHigh-dose cytarabineCombination of rituximabGranulocyte colony-stimulating factorCollection of PBSCStem cell mobilizationMantle cell lymphomaColony-stimulating factorHD chemotherapyPeripheral CD19Concurrent administrationIndolent lymphomaPeripheral bloodPatients PCRProfound depletionCell mobilizationMedian number